Literature DB >> 17628306

Markers of detection.

Edward Messing1.   

Abstract

Three applications of markers of detection: screening, replacing surveillance cystoscopies, and guiding evaluation of asymptomatic hematuria, are discussed. In one study, repetitive hematuria screening in men age >or=50 effectively shifted the stage of high grade cancers at diagnosis from muscle invasive to earlier ones, reducing bladder cancer, and all cause mortality. This technique is sensitive, but is not terribly specific. Testing other markers alone or in combination with each other and/or hemoglobin screening in similar or higher risk populations is now beginning. Currently, no commercially available marker is sufficiently sensitive to replace all surveillance cystoscopies for low risk bladder cancer, although some cystoscopic examinations can probably be replaced by markers. Available markers are too insensitive for small, high grade cancers to replace any surveillance cystoscopies in this group. No single marker or combination of markers can safely replace cystoscopy in the work-up of patients with microhematuria who are at high risk for harboring bladder cancer. However, markers may be useful for directing which patients age <or=40 with asymptomatic microhematuria without histories of smoking, particularly women, require cystoscopic evaluation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17628306     DOI: 10.1016/j.urolonc.2007.05.012

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  9 in total

1.  UroSEEK gene panel for bladder cancer surveillance.

Authors:  Regan Wong; Charles J Rosser
Journal:  Transl Androl Urol       Date:  2019-12

Review 2.  Potential new urinary markers in the early detection of bladder cancer.

Authors:  Samir P Shirodkar; Vinata B Lokeshwar
Journal:  Curr Opin Urol       Date:  2009-09       Impact factor: 2.309

Review 3.  Long-term outcome of home dipstick testing for hematuria.

Authors:  Ralph Madeb; Edward M Messing
Journal:  World J Urol       Date:  2007-11-27       Impact factor: 4.226

4.  FGFR3b Extracellular Loop Mutation Lacks Tumorigenicity In Vivo but Collaborates with p53/pRB Deficiency to Induce High-grade Papillary Urothelial Carcinoma.

Authors:  Haiping Zhou; Feng He; Cathy L Mendelsohn; Moon-Shong Tang; Chuanshu Huang; Xue-Ru Wu
Journal:  Sci Rep       Date:  2016-05-09       Impact factor: 4.379

Review 5.  Aberrantly expressed microRNAs in the context of bladder tumorigenesis.

Authors:  Jong-Young Lee; Dong-Sung Ryu; Wun-Jae Kim; Seong-Jin Kim
Journal:  Investig Clin Urol       Date:  2016-06-10

Review 6.  Immune checkpoint blockade therapy for bladder cancer treatment.

Authors:  Jayoung Kim
Journal:  Investig Clin Urol       Date:  2016-05-26

Review 7.  Unmasking molecular profiles of bladder cancer.

Authors:  Xuan-Mei Piao; Young Joon Byun; Wun-Jae Kim; Jayoung Kim
Journal:  Investig Clin Urol       Date:  2018-02-01

8.  Identification of differentially expressed miRNAs and miRNA-targeted genes in bladder cancer.

Authors:  Jong-Young Lee; Seok Joong Yun; Pildu Jeong; Xuan-Mei Piao; Ye-Hwan Kim; Jihye Kim; Sathiyamoorthy Subramaniyam; Young Joon Byun; Ho Won Kang; Sung Phil Seo; Jayoung Kim; Jung Min Kim; Eun Sang Yoo; Isaac Y Kim; Sung-Kwon Moon; Yung Hyun Choi; Wun-Jae Kim
Journal:  Oncotarget       Date:  2018-02-07

Review 9.  Liquid Biopsy Biomarkers in Urine: A Route towards Molecular Diagnosis and Personalized Medicine of Bladder Cancer.

Authors:  Matteo Ferro; Evelina La Civita; Antonietta Liotti; Michele Cennamo; Fabiana Tortora; Carlo Buonerba; Felice Crocetto; Giuseppe Lucarelli; Gian Maria Busetto; Francesco Del Giudice; Ottavio de Cobelli; Giuseppe Carrieri; Angelo Porreca; Amelia Cimmino; Daniela Terracciano
Journal:  J Pers Med       Date:  2021-03-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.